Physician profile
John C Bausher
NPI 1033207824
$4,422.93
in general payments reported to CMS, 2019-2025
35 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $141 · 2021: $401 · 2022: $944 · 2023: $1,056 · 2024: $896 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.91 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $747.74 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $361.53 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $322.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $297.42 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $292.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.17 | 2020-2025 | Jardiance, Ofev, Glyxambi |
| Janssen Pharmaceuticals, INC | $196.92 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $191.66 | 2019-2022 | |
| Abbvie INC. | $175.15 | 2019-2023 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $170.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $164.94 | 2019-2024 | |
| Sanofi Pasteur INC. | $137.67 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $136.75 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $131.17 | 2019-2025 | Jardiance, Mounjaro |
| Dexcom, INC. | $106.17 | 2019-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.11 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $76.67 | 2023-2024 | Freestyle Libre 3 |
| Allergan, INC. | $69.36 | 2019-2020 | |
| Mylan Specialty L.P. | $66.88 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $44.79 | 2022-2023 | Myrbetriq |
| Viatris Specialty LLC | $43.64 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $42.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $40.40 | 2023 | Rexulti |
| Shield Therapeutics INC | $38.92 | 2023-2024 | Accrufer |
| Arbor Pharmaceuticals, INC. | $26.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.32 | 2019 | |
| Vanda Pharmaceuticals INC. | $20.96 | 2019 | |
| Esperion Therapeutics, INC. | $20.75 | 2020 | |
| Exact Sciences Corporation | $20.48 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.90 | 2019 | |
| Nevro Corp. | $17.48 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $17.05 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.79 | 2022 | |
| Hologic Sales and Service, LLC | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bausher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.